Malhi, GS, Bassett, D, Boyce, P, Bryant, R, Fitzgerald, PB, Fritz, K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry
2015; 49: 1087–206.
Gaynes, BN, Warden, D, Trivedi, MH, Wisniewski, SR, Fava, M, Rush, AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv
2009; 60: 1439–45.
Malhi, GS, Byrow, Y. Is treatment-resistant depression a useful concept?
Evid Based Mental Health
2016; 19: 1–3.
Crown, WH, Finkelstein, S, Berndt, ER, Ling, D, Poret, AW, Rush, AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry
2002; 63: 963–71.
Domino, EF. Taming the ketamine tiger. Anesthesiology
2010; 113: 678–86.
Sanacora, G, Schatzberg, AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?
2015; 40: 259–67.
Li, JH, Vicknasingam, B, Cheung, YW, Zhou, W, Nurhidayat, AW, Jarlais, DC, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil
2011; 2: 11–20.
Berman, RM, Cappiello, A, Anand, A, Oren, DA, Heninger, GR, Charney, DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry
2000; 47: 351–4.
Zarate, CA, Singh, JB, Carlson, PJ, Brutsche, NE, Ameli, R, Luckenbaugh, DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry
2006; 63: 856–64.
Duman, RS, Monteggia, LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry
2006; 59: 1116–27.
Caddy, C, Amit, BH, McCloud, TL, Rendell, JM, Furukawa, TA, McShane, R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev
2015; 9: CD01162.
McGirr, A, Berlim, MT, Bond, DJ, Fleck, MP, Yatham, LN, Lam, RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med
2015; 45: 693–704.
Lee, EE, Della Selva, MP, Liu, A, Himelhoch, S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry
2015; 37: 178–84.
Murrough, JW, Perez, AM, Pillemer, S, Stern, J, Parides, MK, aan het Rot, M, et al. Rapid and longer-term antidepressant effects of repeated Ketamine infusions in treatment-resistant major depression. Biol Psychiatry
2013; 74: 250–6.
Diamond, PR, Farmery, AD, Atkinson, S, Haldar, J, Williams, N, Cowen, PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol
2014; 28: 536–44.
Price, RB, Mathew, SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs
2015; 29: 181–8.
Murrough, JW, Soleimani, L, DeWilde, KE, Collins, KA, Lapidus, KA, Iacoviello, BM, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med
2015; 45: 3571–80.
Soleimani, L, Welch, A, Murrough, JW. Does ketamine have rapid anti-suicidal ideation effects?
Curr Treat Options Psych
2015; 2: 383–93.
McCloud, TL, Caddy, C, Jochim, J, Rendell, JM, Diamond, PR, Shuttleworth, C, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev
2015; 9: CD011611.
Diazgranados, N, Ibrahim, L, Brutsche, NE, Newberg, A, Kronstein, P, Khalife, S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry
2010; 67: 793–802.
Zarate, CA, Brutsche, NE, Ibrahim, L, Franco-Chaves, J, Diazgranados, N, Cravchik, A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry
2012; 71: 939–46.
Schatzberg, AF. A word to the wise about ketamine. Am J Psychiatry
2014; 171: 262–4.
Liao, Y, Tang, J, Ma, M, Wu, Z, Yang, M, Wang, X, et al. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain
2010; 133: 2115–22.
Olney, JW, Labruyere, J, Wang, G, Wozniak, DF, Price, MT, Sesma, MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science
1991; 254: 1515–8.
Wan, L-B, Levitch, CF, Perez, AM, Brallier, JW, Iosifescu, DV, Chang, LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry
2015; 76: 247–52.
Niesters, M, Martini, C, Dahan, A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol
2014; 77: 357–367.
Majewski-Tiedeken, CR, Rabin, CR, Siegel, SJ. Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains. Drug Alcohol Depend
2008; 92: 217–27.
Rush, JA. Ketamine for treatment-resistant depression: ready or not for clinical use?
Am J Psychiatry
2013; 170: 1079–81.
Moore, JW, Cambridge, VC, Morgan, H, Giorlando, F, Adapa, R, Fletcher, PC. Time, action and psychosis: using subjective time to investigate the effects of ketamine on sense of agency. Neuropsychologia
2013; 51: 377–84.
Lapidus, KAB, Levitch, CF, Perez, AM, Brallier, JW, Parides, MK, Soleimani, L, et al. A randomized controlled trial of Intranasal Ketamine in major depressive disorder. Biol Psychiatry
2014; 76: 970–6.
Schoevers, RA, Chaves, TV, Balukova, SM, aan het Rot, M, Kortekaas, R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry
2016; 208: 108–13.
Rasmussen, KG, Lineberry, TW, Galardy, CW, Kung, S, Lapid, MI, Palmer, BA, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol
2013; 27: 444–50.
Frye, MA, Blier, P, Tye, SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol
2015; 35: 334–6.
Kaufman, KR. Ethical considerations in placebo-controlled randomized clinical trials. Br J Psychiatry Open
2015; 1: e3–4.
Schak, KM, Vande Voort, JL, Johnson, EK, Kung, S, Leung, JG, Rasmussen, KG, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry
2016; 173: 215–8.
Li, CT, Chen, MH, Lin, WC, Hong, CJ, Yang, BH, Liu, RS, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp
2016; 37: 1080–90.
Harraz, MM, Tyagi, R, Cortés, P, Snyder, SH. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry
2016; 21: 313–9.
Preskorn, S, Macaluso, M, Mehra, DO, Zammit, G, Moskal, JR, Burch, RM, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract
2015; 21: 140–9.
Newport, DJ, Carpenter, LL, McDonald, WM, Potash, JB, Tohen, M, Nemeroff, CB, et al. APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry
2015; 172: 950–66.
Malhi, GS, Lingford-Hughes, AR, Young, AH. Antidepressant treatment response: ‘I want it all, and I want it now’
Br J Psychiatry
2016; 208: 101–103.